Roche Diagnostics Gmbh

Other

Boehringer Mannheim Gmbh

Roche Molecular Systems, Inc.

Helmut Rosemeyer

Frank Seela

Dieter Heindl

Frank Bergmann

Enno Schweinberger

Herbert Von Der Eltz

Alfred Mertens

Harald Zilch

Rainer Gumbiowski

Bernhard Konig

Edith Koch

Klasu Muhlegger

Angelika Roling

Werner Bourgeouis

The invention relates to a method for isolating and/or identifying known or unknown, nucleic acid sequences (target sequences) which are marked, optionally, with reporter groups, by base specific hybridisation with, essentially, complementary sequences, which belong to a library or sequences. The sample sequences are characterised in that they support, on one of the termini thereof (5'-ends or 3&#x2032;-ends, preferably on 5&#x2032;-ends), a single double or multi-chained lipid part, which spreads in a monomolecular layer on a liquid gas or liquid-liquid phase boundary layer. The invention also relates to a system for detecting or isolating nucleic acids.

Nucleolipids and use thereof, and devices for nucleic acid analysis

Within oligonucleotides, 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids with homogenous stability. This is useful for the adaptation of the stabilities of different oligonucleotide sequences in all kinds of hybridization techniques, for example in oligomer chip technology.

2-Azapurine compounds and their use

Within oligonucleotides 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids with homogenous stability. This is useful for the adaptation of the stabilities of different oligonucleotide sequences in all kinds of hybridization techniques, for example in oligomer chip technology.

2-azapurine compounds and their uses

Oligodeoxyribonucleotides in which at least two 2&prime;-deoxy-&bgr;-D-erythro-pentofuranosyl groups are replaced by 2&prime;-deoxy-&bgr;-D-threo-pentofuranosyl groups at both the 5&prime; end and 3&prime; end, and oligodeoxyribonucleotides in which at least 20% of the 2&prime;-deoxy-&bgr;-D-erythro-pentofuranosyl groups in consecutive nucleotide building blocks are replaced by 2&prime;-deoxy-&bgr;-D-threo-pentofuranosyl groups and which are composed of 6 to 100 nucleotide building blocks, are suitable for the inhibition of the expression of viral genes and oncogenes by the antisense principle and can be used for the production of pharmaceutical agents with antiviral activity.

Oligo-2&prime;-deoxynucleotides and their use as pharmaceutical agents with antiviral activity

Purine analog nucleoside and nucleotide compounds

Growing community of inventors

Osnabruck, Germany

Helmut Rosemeyer